Table 1.
Baseline characteristics of included trials for platelet reactivity outcomes
| Trial | Year | N | Comparison | SD or HD (DAPT group) | Mean age (years) | Follow-up (days) |
|---|---|---|---|---|---|---|
| ACCEL-AMI29 | 2009 | 90 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | Both | 62 | 30 |
| ACCEL-LOADING-ACS30 | 2012 | 218 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | SD | 63 | 30 |
| ACCEL-POLYMORPHISM31 | 2010 | 134 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | HD | 63 | 30 |
| ACCEL-PPI32 | 2012 | 90 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | HD | NR | 30 |
| ACCEL-RESISTANCE33 | 2009 | 60 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | HD | 63 | 30 |
| CILON-T34 | 2011 | 716 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | SD | 64 | 180 |
| Gao et al35 | 2013 | 428 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | SD | 56 | 365 |
| Guan et al36 | 2012 | 840 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | SD | 60 | 30 |
| HOST-ASSURE37 | 2013 | 1356 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | Both | 63 | 30 |
| Jeong et al38 | 2014 | 275 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | Both | NR | 30 |
| Jin et al39 | 2012 | 60 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | HD | 62 | 30 |
| Kim et al40 | 2011 | 126 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | HD | 62 | 30 |
| Kim et al41 | 2007 | 60 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | SD | 63 | 30 |
| Kum et al42 | 2009 | 66 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | SD | 62 | 14 |
| Lee et al43 | 2010 | 63 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | Both | NR | 14 |
| PIANO-2 CKD44 | 2011 | 74 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | Both | 53 | 14 |
| Shim et al45 | 2009 | 379 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | SD | 61 | 14 |
ACCEL-AMI, adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in patients with AMI; ACCEL-LOADING-ACS, Multicentre Randomised Trial Evaluating Efficacy of Cilostazol on Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients; ACCEL-POLYMORPHISM, Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention; ACCEL-PPI, Pharmacodynamics Effects of Adding Cilostazol versus Double-dose Clopidogrel in Patients with Acute Myocardial Infarction During Proton Pump Inhibitor Co-administration; ACCEL-RESISTANCE, Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; HD, high-dose clopidogrel (150 mg); HOST-ASSURE, Harmonising Optimal Strategy for Treatment of Coronary Artery Stenosis—Safety and Effectiveness of Drug-Eluting Stents and Antiplatelet Regimen; NR, not reported; PIANO-2 CKD, Platelet Reactivity in Patients with Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared with a High-Maintenance Dose of Clopidogrel; SD, Standard-dose clopidogrel (75 mg).